Im­prov­ing financial per­for­mance

PA­TRI­CIA CHOU CFO, Fore­see Phar­ma­ceu­ti­cals, Tai­wan

BioSpectrum (Asia) - - Bio Content -

Pa­tri­cia Chou has been serv­ing as Chief Financial Of­fi­cer in Fore­see Phar­ma­ceu­ti­cals Co.,

Ltd. a Tai­wan based clin­i­cal stage phar­ma­ceu­ti­cal com­pany de­vel­op­ing and com­mer­cial­iz­ing new drugs us­ing its pro­pri­etary drug de­liv­ery tech­nol­ogy, since March, 2016. The firm also de­vel­ops first-in-class NCE in dis­ease ar­eas of high unmet med­i­cal needs. The com­pany also re­cently bagged a deal with TRPharm, a lead­ing Turk­ish bio­phar­ma­ceu­ti­cal com­pany for the com­mer­cial­iza­tion of Fore­see’s FP-001 pro­gram in Turkey and cer­tain Mid­dle East coun­tries. Un­der the terms of this part­ner­ship, Fore­see will re­ceive a com­bi­na­tion of mile­stones pay­ments in ad­di­tion to a sig­nif­i­cant share of the prod­uct rev­enue in the ter­ri­tory.

Prior to join­ing Fore­see, Pa­tri­cia, a Cer­ti­fied Pub­lic Ac­coun­tant in Tai­wan, the United States and China, served as the Chief Financial Of­fi­cer, Vice Pres­i­dent of Cor­po­rate De­vel­op­ment, and Spokesper­son of Sci­noPharm Tai­wan. She is also Di­rec­tor in Ta­len­tec In­ter­na­tional co., ltd.

Pa­tri­cia is also lead­ing the IPO process at Fore­see Phar­ma­ceu­ti­cals. Un­der her lead­er­ship the com­pany im­proved the financial per­for­mance, built a strong fi­nance/in­vestor re­la­tions/ M&A team, and also im­ple­mented a num­ber of in­dus­try best-prac­tices in financial re­port­ing, cap­i­tal mar­ket fundrais­ing, cor­po­rate gov­er­nance, M&A, and strate­gic plan­ning.

Speak­ing about chal­lenges in the biotech in­dus­try, Pa­tri­cia Chou, who holds a Master of Busi­ness Ad­min­is­tra­tion from Univer­sity of Cal­i­for­nia, Berke­ley, a Master of Ac­count­ing from Univer­sity of South­ern Cal­i­for­nia, and a Bach­e­lor of Science in Busi­ness Ad­min­is­tra­tion from Na­tional Tai­wan Univer­sity, said “Un­cer­tainty and time pres­sure in this in­dus­try is more se­vere than in high-tech in­dus­tries. Drug de­vel­op­ment is filled with un­cer­tain­ties and the pro­longed R&D phase and ex­tremely high risks makes its fi­nance su­per chal­leng­ing.”

Shar­ing her views on chal­lenges Pa­tri­cia ob­served that the pro­longed R&D phase and ex­tremely high risks of prod­uct de­vel­op­ment in pharma in­dus­try makes its fi­nance su­per chal­leng­ing.

Pa­tri­cia was hon­ored as the “2014 Top 3 Best CFO” in Asia health­care in­dus­try voted by se­cu­rity an­a­lysts in In­sti­tu­tional In­vestor magazine. How­ever, this jour­ney up the lad­der had its unique chal­lenges for a women. “Bal­anc­ing work and fam­ily, is largely a fe­male’s re­spon­si­bil­ity. If I were a male, who does not need to bear or breast feed ba­bies, I might have done bet­ter than now, she added.”

Talk­ing about her achieve­ments Pa­tri­cia said, “As Fore­see’s CFO in the past 1.5 years, I’ve worked on rais­ing more funds, build­ing brand recog­ni­tion in the local and global in­vest­ment com­mu­nity, lead­ing the up­com­ing IPO, and fa­cil­i­tat­ing busi­ness growth.”

Pa­tri­cia says that com­pared to other in­dus­tries that she has been as­so­ci­ated with, biotech in­dus­try of­fers more op­por­tu­ni­ties for women and has more women em­ploy­ees on rolls. “In my ex­pe­ri­ence of deal­ing with other in­dus­tries, I feel the gen­der par­ity in pharma bet­ter as I can see more tal­ented women in ex­ec­u­tive po­si­tions in the com­pa­nies. But, the in­dus­try needs to be even more open, over­look gen­der and re­ward a per­son for their ca­pa­bil­i­ties.”

PA­TRI­CIA CHOU CFO, Fore­see Phar­ma­ceu­ti­cals, Tai­wan

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.